Glucagen Hypokit (Glucagon)

Glucagen Hypokit is indicated for the rapid reversal of severe hypoglycemia when oral carbohydrate intake is not feasible. It is used in emergency settings and by trained caregivers.

• Treatment of acute, severe hypoglycemia in diabetic patients
• Emergency rescue therapy for unconscious or unable-to-eat individuals
• Administration by healthcare professionals in hospital or pre‑hospital environments
• Use by trained non‑medical personnel for home or community rescue situations
• Adjunct to standard diabetes management protocols when hypoglycemia risk is high

Glucagen Hypokit may cause a range of adverse reactions, most of which are transient and resolve without intervention.

Common

• Nausea or vomiting
• Flushing or warmth sensation
• Headache
• Dizziness or light‑headedness
• Injection site pain or erythema
• Transient rise in blood pressure

Serious

• Severe allergic reaction (anaphylaxis)
• Persistent hyperglycemia requiring medical attention
• Cardiac arrhythmias in susceptible individuals
• Hypotension or shock in rare cases

When prescribing or administering Glucagen Hypokit, several safety considerations should be observed.

• Verify the diagnosis of severe hypoglycemia before use
• Ensure proper reconstitution and dosing according to the product label
• Monitor blood glucose levels after administration to avoid hyperglycemia
• Use caution in patients with known hypersensitivity to glucagon or formulation components
• Assess cardiovascular status in patients with a history of heart disease
• Store the lyophilized powder according to manufacturer instructions to maintain potency

Glucagon can interact with other medications, influencing its efficacy or safety profile.

Avoid

• Beta‑blockers, which may blunt the expected rise in blood glucose
• Long‑acting insulin analogues that could prolong hypoglycemia

Use with caution

• Oral hypoglycemic agents (e.g., sulfonylureas) that may increase hypoglycemia risk
• Medications that affect hepatic glycogen stores (e.g., corticosteroids)
• Drugs that alter cardiovascular function, such as calcium channel blockers
• Any agent that may cause allergic cross‑reactivity with glucagon formulations